Phase II Study of Cisplatin Plus Epirubicin Salvage Chemotherapy in Refractory Germ Cell Tumors
To determine the feasibility and toxicity of combining epirubicin to fixed does cisplatin;
to determine the partial and complete response rate and duration of remission; to determine
the toxicity; to ascertain the potential for greater than 12 month continuous disease-free
survival and, therefore, potential curability.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the feasibility and toxicity of combining epirubicin to fixed dose cisplatin
Lawrence Einhorn, M.D.
United States: Institutional Review Board
|Indiana University Cancer Center||Indianapolis, Indiana 46202-5265|